ifb-088
Sephin1 is a guanabenz derivative that binds to and inhibits a regulatory subunit of the stress-induced protein phosphatase 1 (PPP1R15A), but not the constitutive PPP1R15B, and lacks beta2-adrenergic activity. Phosphorylation of eIF2α, α subunit of eukaryotic translation initiation factor 2, reduces protein synthesis and prevents the accumulation of misfolded protein in the endoplasmic reticulum (ER). PPP1R15A recruits the serine/threonine-protein phosphatase PP1 to dephosphorylate eIF2α, so inhibiting PPP1R15A activity prolongs the phosphorylation of eIF2α and aids in its prevention of the accumulation of misfolded protein. In vitro, Sephin1 protected cells from lethal protein misfolding and cytotoxic ER stress. In vivo Sephin1 prevented Charcot-Marie-Tooth 1B and ALS diseases in mice. — NCATS
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Earliest trial started Jun 21, 2018 (NCT03610334)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
SMILES
NC(=N)N\N=C\C1=CC=CC=C1Cl- Mol. weight
- 196.637 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS9M998304JB ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05508074 | Phase 2 | Nov 30, 2022 | CHU La Timone, InFlectis BioScience, University of Milan |
| NCT03610334 | Phase 1 | Jun 21, 2018 | Aix-University of Marseille, InFlectis BioScience, Qualissima, STRAGEN |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| InFlectis BioScience | For profit | 2 | 2 | 2 | 2018 |
| Aix-University of Marseille | Academic/Hospital | 1 | 0 | 1 | 2018 |
| CHU La Timone | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Qualissima | For profit | 1 | 0 | 1 | 2018 |
| STRAGEN | For profit | 1 | 0 | 1 | 2018 |
| University of Milan | Academic/Hospital | 1 | 0 | 1 | 2022 |